Tullis Health Investors

Tullis Health Investors of Florida LLC is a private equity firm established in 1986, headquartered in Palm Beach Gardens, Florida. The firm specializes in growth capital investments, primarily within the healthcare sector, focusing on areas such as medical devices, healthcare services, biotechnology, and specialty pharmaceuticals. Tullis Health Investors targets small to mid-sized companies, providing equity and equity-related capital from seed through late-stage funding. The firm typically invests between $0.25 million and $10 million in companies that have established operations or are well into their product development processes. Its investment strategy includes a focus on healthcare infrastructure, distribution, and information technology, as well as therapeutic devices. Tullis Health Investors primarily invests in U.S. companies, particularly those located in the Midwest, Michigan, Connecticut, Alabama, Albuquerque, and New Mexico.

Das Narayandas Ph.D

Venture Partner

Jim Tullis

Founder and CEO

John Tullis

Partner and CEO

40 past transactions

Exagen

Venture Round in 2019
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

TriSalus Life Sciences

Series C in 2015
TriSalus Life Sciences, based in Westminster, Colorado, focuses on developing innovative drug delivery technologies and immune-oncology therapeutics aimed at improving treatment outcomes for challenging cancers, particularly liver and pancreatic cancer. Founded in 2009, the company specializes in precision infusion systems designed for interventional radiology. Its product offerings include Pressure Enabled Drug Delivery (PEDD) systems, which utilize a unique expandable tip catheter to deliver embolic agents while minimizing damage to healthy tissues. The Surefire infusion systems, including various models for lobar, segmental, and super-selective infusions, aim to enhance tumor uptake through controlled pressure and blood flow management. Additionally, TriSalus is advancing an investigational therapy, nelitolimod, which has shown promise in enhancing immune response against liver tumors. The company continues to innovate with devices like the TriNav, which employs SmartValve technology to optimize drug delivery.

CareSync

Series B in 2015
CareSync is the leading provider of software and services for chronic disease management, combining technology with 24/7 nursing services to facilitate care coordination among patients, family and caregivers and all providers. CareSync provides turnkey Chronic Care Management services and a software-only option, allowing practices of any size to easily meet the billing requirements for CPT code 99490. Additionally, CareSync’s certified technology makes it simple for providers to meet Meaningful Use 2 for Data Exchange, Messaging, and Timely Access. CareSync patients are at the center of their healthcare, with access to health information, actionable goals, and Comprehensive Care Plan tasks, and as a result, are experiencing more productive medical appointments and better health outcomes.

OrthoSensor

Series C in 2015
OrthoSensor is an early-stage medical device company focused on developing and integrating advanced sensor technology in the Orthopedic field. The company is building a portfolio of intelligent, accurate, low-cost, and easy to use products that will extend from the operating room into the lifecycle of the implanted orthopedic device. Its intelligent orthopedic devices utilize advanced proprietary sensor and communications technologies, coupled with the company’s innovative software products, to facilitate evidence-based decisions in orthopedic surgery – with the goal of improving patient outcomes and potentially reducing the cost of treating musculoskeletal disease. It was founded in 2006 and is headquartered in Dania, Florida.

CareSync

Series A in 2014
CareSync is the leading provider of software and services for chronic disease management, combining technology with 24/7 nursing services to facilitate care coordination among patients, family and caregivers and all providers. CareSync provides turnkey Chronic Care Management services and a software-only option, allowing practices of any size to easily meet the billing requirements for CPT code 99490. Additionally, CareSync’s certified technology makes it simple for providers to meet Meaningful Use 2 for Data Exchange, Messaging, and Timely Access. CareSync patients are at the center of their healthcare, with access to health information, actionable goals, and Comprehensive Care Plan tasks, and as a result, are experiencing more productive medical appointments and better health outcomes.

Exagen

Debt Financing in 2014
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

Exagen

Debt Financing in 2013
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

Exagen

Series C in 2012
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

Estech

Venture Round in 2012
Estech is a privately held medical device manufacturing and distribution company based in San Ramon, California. Founded in 1996 by Arthur and Raymond Bertolero, the company focuses on developing and marketing medical devices and disposables that facilitate both traditional and minimally invasive cardiac surgical procedures. Estech has established a global distribution network and is recognized for attracting skilled professionals in the medical device sector. The company's commitment to innovation and quality has enabled it to achieve sustained success in a competitive industry, reflecting the dedication of its team across all departments.

Exagen

Venture Round in 2012
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

Exagen

Venture Round in 2011
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

Exagen

Venture Round in 2011
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

Exagen

Venture Round in 2011
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

Estech

Series D in 2010
Estech is a privately held medical device manufacturing and distribution company based in San Ramon, California. Founded in 1996 by Arthur and Raymond Bertolero, the company focuses on developing and marketing medical devices and disposables that facilitate both traditional and minimally invasive cardiac surgical procedures. Estech has established a global distribution network and is recognized for attracting skilled professionals in the medical device sector. The company's commitment to innovation and quality has enabled it to achieve sustained success in a competitive industry, reflecting the dedication of its team across all departments.

BioBehavioral Diagnostics

Series B in 2010
BioBehavioral Diagnostics specializes in manufacturing diagnostic systems aimed at the quantitative assessment of behavioral and neurobiological disorders. The company is known for its Quotient ADHD System, which provides an objective and accurate evaluation of ADHD symptoms. Through its proprietary platform technology, BioBehavioral Diagnostics measures specific behaviors linked to brain function and inhibitory control deficits, collecting data on an individual's ability to remain still, manage impulsivity, and respond accurately to visual stimuli on a computer screen. The company is committed to delivering valuable information to physicians, parents, and patients, facilitating personalized strategies to improve the quality of life for those affected by ADHD.

Synageva BioPharma

Series F in 2009
Synageva BioPharma is a biopharmaceutical company focused on developing and commercializing innovative protein therapeutics for rare diseases. Utilizing its proprietary Synageva Expression Platform, the company aims to create next-generation therapies that address unmet medical needs in this specialized market. By concentrating on rare diseases, Synageva BioPharma seeks to provide effective treatments and improve the quality of life for patients affected by these conditions.

Coherex Medical

Series B in 2009
Coherex Medical, Inc. develops medical devices for addressing the structural heart disease conditions. It offers patent foramen ovale (PFO) closure system, which is designed to stimulate tissue in-growth to ensure long-term closure of the PFO. The company was founded as Proximare, Inc. in 2003 and changed its name to Coherex Medical, Inc. in 2006. The company is based in Salt Lake City, Utah.

VidaCare

Venture Round in 2009
Vidacare Corporation, a medical device company, engages in the development, manufacture, and marketing of intraosseous access devices for diagnostic, monitoring, and therapeutic applications. The company provides EZ-IO Product System, which is designed to provide controlled vascular access through the intraosseous route to patients in emergent situations when vascular access is challenging and impossible. It also offers EZ-IO power driver, which is designed to penetrate the intraosseous space by drilling through the bone with a hollow needle and integrated stylet that doubles as the forward cutting bit to secure its correct placement; and EZ-IO Vascular Access Pack, a kit developed for emergency medical specialists to provide access to IV and IO devices to gain vascular access. In addition, the company provides a suite of hematology/oncology products, including a power driver and needle sets for bone marrow aspiration and biopsy; and OnControl, a bone marrow system for clinicians to perform bone marrow aspiration and biopsy procedures. Its products are used in pre-hospital, emergency, crash cart, and rapid response applications, as well as in military and homeland security industries. Vidacare Corporation was founded in 2001 and is headquartered in San Antonio, Texas.

Synageva BioPharma

Series F in 2009
Synageva BioPharma is a biopharmaceutical company focused on developing and commercializing innovative protein therapeutics for rare diseases. Utilizing its proprietary Synageva Expression Platform, the company aims to create next-generation therapies that address unmet medical needs in this specialized market. By concentrating on rare diseases, Synageva BioPharma seeks to provide effective treatments and improve the quality of life for patients affected by these conditions.

Intranasal Therapeutics

Series B in 2009
Ikano Therapeutics a specialty pharmaceutical company, focuses on developing nasal spray drug products.

Atritech

Venture Round in 2009
Atritech is a Minneapolis-based private company founded in 2000, specializing in innovative medical technologies aimed at preventing strokes related to atrial fibrillation. The company's flagship product, the WATCHMAN Device, offers a minimally invasive solution for patients with non-valvular atrial fibrillation at risk of stroke by sealing off the left atrial appendage, thereby preventing blood clots from entering the bloodstream. The WATCHMAN Device was first implanted in Germany in 2002 and in the United States in 2003, and has since undergone extensive clinical trials to compare its efficacy against traditional long-term anticoagulation therapies. While the device is CE marked and available in several international markets, it is currently classified for investigational use only within the United States. Atritech's technology aims to enhance the quality of life for patients by providing a permanent alternative to anticoagulant medications.

Aldagen

Series D in 2008
Aldagen is a biopharmaceutical company focused on developing proprietary regenerative cell therapies to address significant unmet medical needs. The company has four product candidates currently in clinical trials. The most advanced candidate, ALD-101, is undergoing a pivotal Phase 3 clinical trial to assess its efficacy in enhancing umbilical cord blood transplants for pediatric patients with inherited metabolic diseases. In addition, Aldagen is conducting or supporting Phase 1 or Phase 1/2 clinical trials for three other candidates: ALD-151, aimed at improving cord blood transplants for leukemia treatment; ALD-301, designed to address critical limb ischemia; and ALD-201, which targets ischemic heart failure.

Atritech

Series D in 2007
Atritech is a Minneapolis-based private company founded in 2000, specializing in innovative medical technologies aimed at preventing strokes related to atrial fibrillation. The company's flagship product, the WATCHMAN Device, offers a minimally invasive solution for patients with non-valvular atrial fibrillation at risk of stroke by sealing off the left atrial appendage, thereby preventing blood clots from entering the bloodstream. The WATCHMAN Device was first implanted in Germany in 2002 and in the United States in 2003, and has since undergone extensive clinical trials to compare its efficacy against traditional long-term anticoagulation therapies. While the device is CE marked and available in several international markets, it is currently classified for investigational use only within the United States. Atritech's technology aims to enhance the quality of life for patients by providing a permanent alternative to anticoagulant medications.

Aldagen

Series C in 2007
Aldagen is a biopharmaceutical company focused on developing proprietary regenerative cell therapies to address significant unmet medical needs. The company has four product candidates currently in clinical trials. The most advanced candidate, ALD-101, is undergoing a pivotal Phase 3 clinical trial to assess its efficacy in enhancing umbilical cord blood transplants for pediatric patients with inherited metabolic diseases. In addition, Aldagen is conducting or supporting Phase 1 or Phase 1/2 clinical trials for three other candidates: ALD-151, aimed at improving cord blood transplants for leukemia treatment; ALD-301, designed to address critical limb ischemia; and ALD-201, which targets ischemic heart failure.

Impulse Monitoring

Series A in 2007
Impulse Monitoring provides a range of intra-operative neurophysiologic monitoring solutions to hospitals and other healthcare facilities. It offers insight into the nervous system during spinal, nerve, and brain-related surgeries. Through the use of its product, IONM, surgeons can reduce surgical risk by providing critical information and alerts on potential harm or compromise to the spinal cord or neural structures. IONM provides better insight into a patient’s condition during surgery to support better decision-making that enables the practice of better medicine. Impulse Monitoring is based in Columbia, Maryland.

BioBehavioral Diagnostics

Series A in 2007
BioBehavioral Diagnostics specializes in manufacturing diagnostic systems aimed at the quantitative assessment of behavioral and neurobiological disorders. The company is known for its Quotient ADHD System, which provides an objective and accurate evaluation of ADHD symptoms. Through its proprietary platform technology, BioBehavioral Diagnostics measures specific behaviors linked to brain function and inhibitory control deficits, collecting data on an individual's ability to remain still, manage impulsivity, and respond accurately to visual stimuli on a computer screen. The company is committed to delivering valuable information to physicians, parents, and patients, facilitating personalized strategies to improve the quality of life for those affected by ADHD.

Adiana

Series D in 2005
Adiana, Inc. is a medical device company based in Redwood City, California, that specializes in the development of permanent contraceptive solutions for women. Founded in 1997, the company focuses on transcervical sterilization systems designed to prevent pregnancy by occluding the fallopian tubes. Its flagship product, Complete TCS, includes a radiofrequency generator, a delivery catheter, and an implantable matrix. This innovative approach offers a non-incisional alternative to traditional tubal ligation, allowing women to avoid the potential side effects and complications associated with other contraceptive methods. As of 2007, Adiana operates as a subsidiary of CYTYC Corp.

Exagen

Series B in 2005
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

Myocor

Series D in 2004
myocor is a medical company that develops and distributes a range of therapeutic products to its clients. The company develops and provides evaluations on technologies to treat mitral regurgitation and heart failure. Furthermore, the technologies assist in the improvement of cardiac function. myocor was founded in 1996 and is based in Minnesota.

Valeo Medical

Series B in 2004
Valeo Medical, Inc., a life sciences company, develops a non-invasive diagnostic blood test for endometriosis. The company was founded in 2003 and is based in Burlington, Massachusetts. Valeo raised money as part of the Discovery Life Sciences fund which was partly funded by the Nashville Capital Network.

BioRexis

Series B in 2004
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.

TransMolecular

Series C in 2004
TransMolecular, Inc. is a neuroscience biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system having inadequate pharmaceutical alternatives. The Company focuses its drug development on cancer and pain, and has built strong technology platforms to enrich its product discovery and development pipeline. Founded in July 1996, TransMolecular is privately held and venture capital backed, having raised $9.6MM to date through two private placements from internationally recognized investment firms. The Company has built a strong management team that is dedicated to the discovery and development of safe and effective products for patients suffering from cancer and pain. Its management team has more than 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance. TransMolecular's corporate offices and R&D laboratories are in Birmingham, Alabama. TransMolecular has received three Small Business Incentive Research (SBIR) grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The Company holds more than 25 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively.

Exagen

Series A in 2004
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.

Valeo Medical

Series A in 2003
Valeo Medical, Inc., a life sciences company, develops a non-invasive diagnostic blood test for endometriosis. The company was founded in 2003 and is based in Burlington, Massachusetts. Valeo raised money as part of the Discovery Life Sciences fund which was partly funded by the Nashville Capital Network.

BioRexis

Series A in 2002
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.

TransMolecular

Series B in 2000
TransMolecular, Inc. is a neuroscience biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system having inadequate pharmaceutical alternatives. The Company focuses its drug development on cancer and pain, and has built strong technology platforms to enrich its product discovery and development pipeline. Founded in July 1996, TransMolecular is privately held and venture capital backed, having raised $9.6MM to date through two private placements from internationally recognized investment firms. The Company has built a strong management team that is dedicated to the discovery and development of safe and effective products for patients suffering from cancer and pain. Its management team has more than 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance. TransMolecular's corporate offices and R&D laboratories are in Birmingham, Alabama. TransMolecular has received three Small Business Incentive Research (SBIR) grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The Company holds more than 25 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively.

SupplyPro

Venture Round in 2000
SupplyPro, Inc. specializes in manufacturing and marketing inventory management solutions aimed at enhancing productivity and efficiency in various industries. The company's offerings include a range of systems such as SupplyAgent for basic material control, SupplyBay designed for harsh industrial settings, and SupplyLocker for managing tools and supplies. Additionally, SupplyLock enables electronic control of cabinets, while SupplyPad provides mobile inventory management for barcoded items. SupplySystem is a modular control system for indirect materials, accompanied by advanced software for intelligent inventory management. Their innovative solutions, including SupplyPro Virtual Inventory Management and SupplyScale, facilitate tracking and management of inventory transactions, even for items not physically present. SupplyPro's products cater to diverse sectors such as automotive, aerospace, energy, and food and beverage, and are used in applications ranging from manufacturing to maintenance. Founded in 1997 and based in San Diego, California, SupplyPro aims to streamline inventory processes while reducing costs and preventing stock-outs.

AmericasDoctor.com

Venture Round in 2000
AmericasDoctor, a unique pharmaceutical services company, combines and integrates leading physician researchers, strategic marketing and consumer outreach capabilities, distinguished hospitals and advanced Internet resources to assist the pharmaceutical industry in developing, positioning and promoting its products. AmericasDoctor was formed in January 2000 from a merger between Affiliated Research Centers (ARC) and AmericasDoctor.com. AmericasDoctor Research Services (formerly ARC) provides investigative site and patient recruitment capabilities through its 150 investigative sites operating in 37 states in the U.S. and five provinces in Canada. Currently, AmericasDoctor is conducting over 550 studies in urology, rheumatology, pulmonology and respiratory disease, endocrinology, cardiology, women’s health, gastroenterology and neuroscience. AmericasDoctor Web Services provides information to consumers in response to health information inquiries. It is the only medical/health Internet site to offer private, real-time, one-on-one chats with board-certified, board-eligible physicians 24 hours a day, seven days a week at no cost to the consumer. This site is sponsored by over 100 leading U.S. hospitals. AmericasDoctor supports the combined efforts of the medical community and pharmaceutical industry to improve the lives of people suffering from chronic illnesses. AmericasDoctor provides the vital link between the patient, the medical expert and the development of new therapies. To the consumer, this means enhanced lives, the empowerment to manage their medical situations and the possibility of improved treatment efficacy. For pharmaceutical companies, this means unique approaches in defining, developing and expediting new products and solutions. AmericasDoctor is a privately held company with a strategic vision to provide a new generation of pharmaceutical services integrating information, marketing and research resources to help create tomorrow’s medicine.

Centromine

Venture Round in 1999
Centromine offers a browser-based, internet-accessed, enterprise-wide software applications and services for the health care market. Its applications allow behavioral health care programs and providers to manage the delivery and associated quality and cost of services completely over the internet.

TransMolecular

Series A in 1997
TransMolecular, Inc. is a neuroscience biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat diseases of the central nervous system having inadequate pharmaceutical alternatives. The Company focuses its drug development on cancer and pain, and has built strong technology platforms to enrich its product discovery and development pipeline. Founded in July 1996, TransMolecular is privately held and venture capital backed, having raised $9.6MM to date through two private placements from internationally recognized investment firms. The Company has built a strong management team that is dedicated to the discovery and development of safe and effective products for patients suffering from cancer and pain. Its management team has more than 75 years of combined relevant experience in healthcare, pharmaceutical development, R&D, operations, and finance. TransMolecular's corporate offices and R&D laboratories are in Birmingham, Alabama. TransMolecular has received three Small Business Incentive Research (SBIR) grants totaling $1 million from the National Institutes of Health for its cancer and pain programs. The Company holds more than 25 patents and/or patent applications to protect its products worldwide, and has exclusive license agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its cancer and pain technology, respectively.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.